Abstract:Abstract Neuroblastoma is a childhood tumor that arises from neuroblasts of the sympathetic nervous system and mostly occurs in adrenal gland. Despite major advances in our understanding of its biology and treatment strategies, malignant neuroblastoma still remains mostly incurable. So, identification of novel molecular targets and exploration of new therapeutic agents are urgently needed. Krüpple-like factor 4 (KLF4) is a transcription factor that shows divergent functions in different malignancies; however, the precise function of KLF4 in malignant neuroblastoma is unclear. In this study, we examined the effects of KLF4 overexpression and apigenin (APG) treatment in human malignant neuroblastoma SK-N-DZ and IMR32 cell lines. We transfected malignant neuroblastoma cells with the plasmid vector overexpressing KLF4 or the control vector and monitored the KLF4 overexpression by staining the cells with FITC conjugated KLF4 antibody and DAPI followed by laser scanning confocal microscopy. Further, KLF4 overexpression in both SK-N-DZ and IMR32 cell lines was confirmed by Western blotting. Then, we determined the reduction in cell viability after transfecting the cells with various concentrations of KLF4 expression vector and treating the cells with APG alone and in combinations. We found that 100 nM KLF4 expression vector and 25 µM APG acted synergistically for most effectively inhibiting the growth of SK-N-DZ and IMR32 cells. We also performed in vitro cell migration assay to monitor inhibition of cell migration and found that combination of KLF4 and APG was highly effective in inhibiting the migration of both neuroblastoma cell lines. Further, we examined the efficacy of combination of KLF4 and APG in induction of apoptosis in SK-N-DZ and IMR32 cells by in situ Wright staining and Annexin V-FITC/PI staining. Combination of KLF4 and APG significantly increased the amounts of apoptosis in both cell lines when compared with control vector or single treatment. We performed more Western blotting to determine the molecular mechanisms for inhibition of cell migration and induction of apoptosis. Matrix metalloproteinases (MMPs), especially MMP2 and MMP9, are responsible for proteolytic processing of extracellular matrix structural proteins and highly implicated in cancer cell migration. We found down regulation of both MMP2 and MMP9 after treatment with combination KLF4 and APG. We also noticed that combination therapy decreased expression of the anti-apoptotic protein Mcl-1, increased expression of the pro-apoptotic proteins Noxa and Puma, and caused activation of caspase-3 for cleavage of ICAD (inhibitor of caspase-activated DNase) leading to completion of apoptosis machinery. Collectively, our results strongly suggest that KLF4 functions as a tumor suppressor and potentiates anti-cancer activities of APG in different human malignant neuroblastoma cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2194. doi:1538-7445.AM2012-2194

Targeting of neuroblastoma cells through Kynurenine‐AHR pathway inhibition

Activation of Aryl Hydrocarbon Receptor by Kynurenine Impairs Progression and Metastasis of Neuroblastoma.

Targeting KDM1A in Neuroblastoma with NCL-1 Induces a Less Aggressive Phenotype and Suppresses Angiogenesis

Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor

Enhancing Retinoic Acid-mediated Effects Through Inhibition of CYP26A1, CYP26B1 and HGF Signaling in Neuroblastoma Cells

Small Molecule Inhibitor Agerafenib Effectively Suppresses Neuroblastoma Tumor Growth in Mouse Models Via Inhibiting ERK MAPK Signaling.

Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance

Revisiting Neuroblastoma: Nrf2, NF-κB and Phox2B as a Promising Network in Neuroblastoma

Targeting Β3-Adrenergic Receptor Signaling Inhibits Neuroblastoma Cell Growth Via Suppressing the Mtor Pathway.

Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro

Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma

Abstract B002: ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma

Suppression of Kynurenine 3-Monooxygenase as a Treatment for Triple-negative Breast Carcinoma

Abstract 2194: KLF4 Overexpression and Apigenin Treatment Inhibited Cell Migration and Induced Apoptosis in Human Malignant Neuroblastoma SK-N-DZ and IMR32 Cells

A Novel Druggable Dual-Specificity tYrosine-Regulated Kinase3/Calmodulin Kinase-like Vesicle-Associated Signaling Module with Therapeutic Implications in Neuroblastoma

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy

Prognostic relevance of high expression of kynurenine pathway markers in glioblastoma

Kynurenine produced by tryptophan 2,3‐dioxygenase metabolism promotes glioma progression through an aryl hydrocarbon receptor‐dependent signaling pathway

TAF1D promotes proliferation by transcriptionally activating G2/M phase‐related genes in MYCN‐amplified neuroblastoma

Abstract 3246: Targeting Syk reprograms tumor-associated macrophages and enhances responses to immune checkpoint blockade and radiation therapy in high-risk neuroblastoma